Literature DB >> 15185716

Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample.

Peter Franks1, Erica I Lubetkin, Marthe R Gold, Daniel J Tancredi, Haomiao Jia.   

Abstract

BACKGROUND: Preference scores for the Medical Outcomes Study (MOS) SF-12 would enable its use in cost-effectiveness analyses. Previous mapping studies of MOS instruments top reference-based instruments have not examined performance in national samples. PARTICIPANTS: 15,000 adults in the 2000 Medical Expenditure Panel Survey annual survey including the SF-12 and EQ-5D Index.
METHODS: Regression of the EQ-5D Index scores onto the physical and mental component summary scores of the SF-12, testing 2nd-4th degree polynomial and spline models, including and excluding sociodemographics.
RESULTS: A 2nd degree polynomial model explained 63% of the variance in EQ-5D scores, with robust internal and external validation. More complex mod-els explained minimally additional variance. Compared with EQ-5D valuations, prediction models overestimated the lowest health states (6% of the population).
CONCLUSIONS: The mapped SF-12 yields usable preference-scaled scores, with some caution for the lowest health states.

Entities:  

Mesh:

Year:  2004        PMID: 15185716     DOI: 10.1177/0272989X04265477

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  54 in total

1.  Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.

Authors:  Mark Parker; Alan Haycox; Jane Graves
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

2.  Estimating utilities for chronic kidney disease, using SF-36 and SF-12-based measures: challenges in a population of veterans with diabetes.

Authors:  Mangala Rajan; Kuan-Chi Lai; Chin-Lin Tseng; Shirley Qian; Alfredo Selim; Lewis Kazis; Leonard Pogach; Anushua Sinha
Journal:  Qual Life Res       Date:  2012-03-06       Impact factor: 4.147

3.  Clinical trials in orthopaedics research. Part III. Overcoming operational challenges in the design and conduct of randomized clinical trials in orthopaedic surgery.

Authors:  Elena Losina; James Wright; Jeffrey N Katz
Journal:  J Bone Joint Surg Am       Date:  2012-03-21       Impact factor: 5.284

4.  Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

5.  Measuring preferences for cost-utility analysis: how choice of method may influence decision-making.

Authors:  Christine M McDonough; Anna N A Tosteson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Self-reported discrimination and mental health status among African descendants, Mexican Americans, and other Latinos in the New Hampshire REACH 2010 Initiative: the added dimension of immigration.

Authors:  Gilbert C Gee; Andrew Ryan; David J Laflamme; Jeanie Holt
Journal:  Am J Public Health       Date:  2006-10       Impact factor: 9.308

7.  US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?

Authors:  I-Chan Huang; Richard J Willke; Mark J Atkinson; William R Lenderking; Constantine Frangakis; Albert W Wu
Journal:  Qual Life Res       Date:  2007-04-06       Impact factor: 4.147

8.  How consistent are health utility values?

Authors:  Pedro L Ferreira; Lara N Ferreira; Luis N Pereira
Journal:  Qual Life Res       Date:  2008-08-08       Impact factor: 4.147

9.  Quality-of-life loss of people admitted to burn centers, United States.

Authors:  Ted Miller; Soma Bhattacharya; William Zamula; Dennis Lezotte; Karen Kowalske; David Herndon; James Fauerbach; Loren Engrav
Journal:  Qual Life Res       Date:  2012-12-08       Impact factor: 4.147

10.  Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).

Authors:  X Badia; M Roset; E Valassi; H Franz; A Forsythe; S M Webb
Journal:  Qual Life Res       Date:  2013-03-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.